SLC16A4 and pulmonary fibrosis: In summary, our findings highlight lactate metabolism, particularly via SLC16A4 and PDGFC–PDGFRA signaling, as a potential driver of COVID‐19–associated pulmonary fibrosis and a promising target for future therapeutic intervention.